Skip to content
mapperlab
← Dashboard
Stock

SLDB

Solid Biosciences Inc.
Latest close $6.517 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
7
27 funds tracked
Ever held
7
Current + past
New this quarter
0
Exited this quarter
0

Marquee-fund ownership over time

Aug 9, 2024Nov 14, 2024Aug 13, 2025Feb 17, 2026
Now
7

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Renaissance Technologies re-entered$7.38$6.51-12%
Citadel Advisors$8.35$6.51-22%
Two Sigma Investments$8.35$6.51-22%
Millennium Management$8.35$6.51-22%
Point72 Asset Management re-entered$8.35$6.51-22%
AQR Capital Management re-entered$5.31$6.51+23%
D.E. Shaw re-entered$4.03$6.51+62%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at Solid Biosciences Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
7
Filings · last 90d
30
Total on file
330
Recent SEC buffer
Most recent
Apr 21, 2026

30d / 90d windows measured from Apr 21, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 330 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · Solid Biosciences Inc.

Annual figures sourced directly from Solid Biosciences Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$8.09M
FY2022-41% YoY
Net income
-$117.22M
FY2019-57% YoY
EPS (diluted)
$-1.99
FY2025+35% YoY
Free cash flow(?)
-$157.44M
FY2025-56% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for Solid Biosciences Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
D.E. ShawQ1 2026open$5.50$6.51+18%
Renaissance TechnologiesQ4 2025open$4.30$6.51+51%
AQR Capital ManagementQ2 2025open$2.59$6.51+151%
Point72 Asset ManagementQ2 2025open$2.59$6.51+151%
D.E. ShawQ1 2025Q2 2025$4.03$2.59-36%
AQR Capital ManagementQ4 2024Q1 2025$5.31$4.03-24%
Citadel AdvisorsQ3 2024open$8.35$6.51-22%
Two Sigma InvestmentsQ3 2024open$8.35$6.51-22%
Millennium ManagementQ3 2024open$8.35$6.51-22%
Point72 Asset ManagementQ3 2024Q1 2025$8.35$4.03-52%
Renaissance TechnologiesQ3 2024Q3 2025$7.38$6.68-9%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.